Board of Directors
J. Alex Martin
Chairman of the Board
A 40-year, veteran corporate executive of the healthcare and medical device industries, Mr. Martin brings an accomplished track record for growing corporate revenue and successfully transforming global businesses. Mr. Martin was the President and CEO of Coherex Medical, where he led the company to a successful exit with Biosense Webster (a Johnson and Johnson company), in November 2015. Prior to Coherex, Mr. Martin was the President and CEO of WorldHeart Corporation, where he led the company to a successful exit with HeartWare in August 2012. Previously, Mr. Martin has held senior leadership roles with Edwards Lifesciences, Cordis Corporation, a Johnson & Johnson Company, and SonaMed Corporation. Mr. Martin holds a bachelor’s degree from the University of Kentucky.
Andrew ElBardissi, M.D.
Dr. ElBardissi has significant investment experience in the healthcare sector. He is currently an investor on the Private Transactions team at Deerfield Management Company and has previously held roles as an early stage life-sciences venture investor and investment banker. He received residency training in General Surgery at Harvard Medical School’s Brigham and Women’s Hospital and in Cardiothoracic Surgery at Stanford University. Dr. ElBardissi has been independently funded by the National Institutes of Health and the Agency for Healthcare Research and Quality, has over 30 publications in leading peer reviewed scientific journals and as presented his research at numerous medical and surgical conferences.
Ms. Walker joined Baird Capital’s Venture Capital team in 2013 and focuses on healthcare investments. Ms. Walker is a current member of the Board of Directors at Palyon Medical Corporation, NeuMoDx, and Molecular Imaging. Prior to joining Baird Capital, she managed the strategic planning, market development, and product portfolio initiatives for multiple brands in discrete and continuous blood glucose monitoring for Abbott Ventures. Previously, Ms. Walker was with ONSET Ventures, specializing in seed and early-stage healthcare technology investments. At Guidant Corporation, Ms. Walker held roles in operations, product design & development, engineering management, and marketing. Ms. Walker’s educational background includes a BS in Mechanical Engineering from Stanford University, an MBA from the Kellogg School of Management and an MEM (Masters of Engineering Management) from the McCormick School of Engineering at Northwestern University.
Mr. Chung has over twenty-five years of hospital-focused, global medical device and pharmaceutical leadership, most recently serving in the role as Chief Commercial Officer for AcelRx Pharmaceuticals. Prior to AcelRx, Mr. Chung served as Chief Commercial Officer for Conceptus (Bayer), where he oversaw the strategic and day-to-day leadership for a 150-member global sales and marketing team. Prior to Conceptus, Mr. Chung served as President and CEO of Mitralis, an early-stage mitral valve repair company. He previously held roles of Vice President North America Sales and Marketing, and Global Vice President, Commercial Operations, for the Heart Valve Therapy business at Edwards Lifesciences. Mr. Chung began his career in the commercial organization at Pfizer Pharmaceuticals. Mr. Chung also served as a PATRIOT missile officer in the U.S. Army, with multiple distinctions, including Airborne, Desert Storm Veteran and Bronze Star Medal. He received his Bachelor of Science degree from the United States Military Academy at West Point.
Mr. Tansey is a managing member of U.S. Venture Partners, a leading Silicon Valley venture capital firm. Mr. Tansey brings significant experience in entrepreneurial, early stage, medical device companies to our NeoChord Board of Directors. Prior to joining USVP, Mr. Tansey was President and CEO of Epicor Medical, a medical device company that developed a minimally invasive treatment for atrial fibrillation and was acquired by St. Jude Medical in 2004. Prior to Epicor, he was President and CEO of Heartport Inc., an innovator of minimally invasive cardiac surgery products. Heartport was acquired by Johnson & Johnson in 2001. Previously, Mr. Tansey served as Vice President, North American Sales for Baxter Edwards’ Cardiovascular products, including heart valves and oxygenators. Mr. Tansey’s educational background includes a B.S. and M.B.A from The College of Notre Dame in Belmont, California.